White Paper

Spray Drying To Enable New Inhaled Drug Products

Source: Catalent

By Lliralyn M. McEachern, BSc; Thomas S. Lund, BSc ;and Alan B. Watts, PhD; Catalent Pharma Solutions


The spray-drying process enables the production of powders with a tightly controlled range of particle sizes and solid- state properties. Formulators have control over the crystalline and amorphous character as well as the radial distribution of components and particle morphology.

Successfully designing an inhaled formulation and the associated spray-drying process requires thoughtful consideration on a number of key process inputs and variables. Atomization, solution composition, solvent and excipient selection, and particle collection are some of the factors that have the largest influence on material properties.

The particle size of the drug product is critical for inhaled therapies, and optimizing these variables to manufacture particles of the targeted size requires understanding the properties of the ingoing API, the utility of the available excipients, and the process parameters connected to product quality attributes. Learn how advanced considerations for the formulation and spray drying process can help manufacture a stable, highly respirable powder and deliver products that require high drug load, a biologic, or rapid onset therapeutic.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online